Vosevi

Active Ingredient(s): Sofosbuvir + Velpatasvir + Voxilaprevir
FDA Approved: * July 18, 2017
Pharm Company: * GILEAD SCIENCES INC
Category: Hepatitis

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4] References .mw-parser-output .reflist{fon... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vosevi Oral Tablet, Film Coated

NDC: 61958-2401

Labeler:

Gilead Sciences, Inc.